Effect of Adoptive Immunotherapy with DC-CIK Cells Combined with XELOX Chemotherapy on Patients with Advanced Colorectal Cancer
Objective To explore the clinical effect of adoptive immunotherapy of dendritic cell-induced killer(DC-CIK)cells and chemotherapy with XELOX regimen in patients with advanced colorectal cancer.Methods A total of 98 patients with advanced colorectal cancer admitted to Suzhou Benq Hospital from February 2019 to March 2022 were selected as the research objects.According to the coin tossing method,they were divided into two groups,49 cases in each group.The reference group was treated with chemotherapy alone,and the study group was treated with DC-CIK cell adoptive immunotherapy+XELOX regimen chemotherapy.The treatment results of the two groups were compared.Results After treatment,the disease remission rate(63.27%)and disease control rate(75.51%)in the study group were better than those in the reference group(40.82%and 55.10%,respectively),and the differences were sta-tistically significant(χ2=4.947,4.503,both P<0.05).After treatment,the levels of natural killer cell,CD3+and CD4+in the study group were higher than those in the reference group,and the level of CD8+was lower than that in the refer-ence group,and the differences were statistically significant(all P<0.05).After treatment,the levels of interleukin-2 and tumour necrosis factor-α and interferon-γ in the study group were higher than those in the reference group,and the differences were statistically significant(all P<0.05).Conclusion After adopting DC-CIK cell adoptive immuno-therapy plus XELOX chemotherapy for advanced colorectal cancer patients,the comprehensive effect is obvious.
DC-CIK cell adoptive immunityXELOX regimen chemotherapyAdvanced colorectal cancer
NETL
NSTL
万方数据
